“…Moreover, nitrofurans proved to be versatile synthetic intermediates en route to other furan derivatives that were accessed via nucleophilic substitution of the nitro group [ 21 ]. A few years ago, we [ 22 , 23 ] and others [ 24 ] have already explored this strategy successfully by conjugating privileged [ 25 ] aminoalkylimidazoles, 1,2,4-oxadiazoles, and pyrimidines to 5-nitrofuranoyl moiety, which resulted in compounds that were found to be antibacterial. Considering the intrinsic association of the GBB reaction-derived imidazo-fused scaffold with antibacterial activity, as demonstrated by the biological profile of compound 3 , combining the cluster of imidazo-fused scaffolds amenable by the GBB reactions with the known antibacterial pharmacophores such as 5-nitrofuryl moiety, surprisingly, has not been exploited to-date and clearly presents itself as a viable and well substantiated research opportunity.…”